Fol. Biol. 2024, 70, 53-61
https://doi.org/10.14712/fb2024070010053
Gallic Acid Alleviates Psoriasis Keratinization and Inflammation by Regulating BRD4 Expression
References
1. , N. A., El-Shishtawy, R. M., Asiri, A. M. (2020) Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: a review. Eur. J. Med. Chem. 204, 112609.
<https://doi.org/10.1016/j.ejmech.2020.112609>
2. , C., Madonna, S., Gisondi, P. et al. (2018) The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol. 9, 1549.
<https://doi.org/10.3389/fimmu.2018.01549>
3. , E., Mochalova, Y., Mayer, A. (2022) BRD4: a general regulator of transcription elongation. Transcription 13, 70-81.
<https://doi.org/10.1080/21541264.2022.2108302>
4. , A. W., Read, C. (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323, 1945-1960.
<https://doi.org/10.1001/jama.2020.4006>
5. , J., Zhang, Y., Tang, C. et al. (2021) Gallic acid: pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomed. Pharmacother. 133, 110985.
<https://doi.org/10.1016/j.biopha.2020.110985>
6. , H., Nagpal, M., Singh, M. et al. (2020) Treatment of psoriasis: a comprehensive review of entire therapies. Curr. Drug Saf. 15, 82-104.
<https://doi.org/10.2174/1574886315666200128095958>
7. , F., Mintoff, D., Del Marmol, V. (2019) Psoriasis: keratinocytes or immune cells – which is the trigger? Dermatology 235, 91-100.
<https://doi.org/10.1159/000495291>
8. , A., Mufti, A., Sibbald, R. G. (2019) Diagnosis and management of cutaneous psoriasis: a review. Adv. Skin Wound Care 32, 58-69.
<https://doi.org/10.1097/01.ASW.0000550592.08674.43>
9. , A. P. G. (2021) Fighting coronaviruses with natural polyphenols. Biocatal. Agric. Biotechnol. 37, 102179.
<https://doi.org/10.1016/j.bcab.2021.102179>
10. , T., Kitoh, A., Otsuka, A. et al. (2018) The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 19, 1286-1298.
<https://doi.org/10.1038/s41590-018-0256-2>
11. , K. D. C. M., dos Santos Lisboa, L., Queiroz, M. F. et al. (2022) Antioxidant activity of fucoidan modified with gallic acid using the redox method. Mar. Drugs 20, 490.
<https://doi.org/10.3390/md20080490>
12. , B., Lorenzini, E., Ciarrocchi, A. et al. (2018) BRD4 and cancer: going beyond transcriptional regulation. Mol. Cancer 17, 164.
<https://doi.org/10.1186/s12943-018-0915-9>
13. , Y., Piao, C. H., Hyeon, E. et al. (2019) Gallic acid alleviates nasal inflammation via activation of Th1 and inhibition of Th2 and Th17 in a mouse model of allergic rhinitis. Int. Immunopharmacol. 70, 512-519.
<https://doi.org/10.1016/j.intimp.2019.02.025>
14. , H., Gooderham, M., Romiti, R. (2022) Diagnosis of generalized pustular psoriasis. Am. J. Clin. Dermatol. 23, 31-38.
<https://doi.org/10.1007/s40257-021-00652-1>
15. , K., Ito, T., Tsuji, G. et al. (2019) Psoriasis and the TNF/IL23/IL17 axis. G. Ital. Dermatol. Venereol. 154, 418-424.
16. , M., Furue, K., Tsuji, G. et al. (2020) Interleukin-17A and keratinocytes in psoriasis. Int. J. Mol. Sci. 21, 1275.
<https://doi.org/10.3390/ijms21041275>
17. , R. L., Zeng, C. W., Li, Y. Q. (2021) Research advances in the mechanisms of BRD4 and its inhibitors in hematologic malignancies – Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 29, 1365-1368.
18. , C. E. M., Armstrong, A. W., Gudjonsson, J. E. et al. (2021) Psoriasis. Lancet 397, 1301-1315.
<https://doi.org/10.1016/S0140-6736(20)32549-6>
19. , Z., Ma, Y., Chen, X. et al. (2022) Protective effects of intestinal gallic acid in neonatal dairy calves against extended-spectrum beta-lactamase producing enteroaggregative Escherichia coli infection: modulating intestinal homeostasis and colitis. Front. Nutr. 9, 864080.
<https://doi.org/10.3389/fnut.2022.864080>
20. , P., Wang, M., Gao, H. et al. (2021) The role of helper T cells in psoriasis. Front. Immunol. 12, 788940.
<https://doi.org/10.3389/fimmu.2021.788940>
21. , Y., Pei, J., Zheng, Y. et al. (2022) Gallic acid: a potential anti-cancer agent. Chin. J. Integr. Med. 28, 661-671.
<https://doi.org/10.1007/s11655-021-3345-2>
22. , X., Yan, Y., Wang, D. et al. (2018) DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. Mol. Cell 71, 592-605.e4.
<https://doi.org/10.1016/j.molcel.2018.06.036>
23. , G. S., Eder, L., Aydin, S. Z. et al. (2021) Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J. Rheumatol. 48, 1208-1220.
<https://doi.org/10.3899/jrheum.201471>
24. , K., Kishimoto, M., Sugai, J. et al. (2019) Risk factors for the development of psoriasis. Int. J. Mol. Sci. 20, 4347.
<https://doi.org/10.3390/ijms20184347>
25. , Y., Tian, J., Wu, T. (2021) BRD4 in physiology and pathology: “BET” on its partners. Bioessays 43, e2100180.
<https://doi.org/10.1002/bies.202100180>
26. , J., Wang, Y., Wang, J. et al. (2023) Circ_0082476 targets miR-138-5p to promote proliferation, invasion, migration and inflammation in IL-22-treated human keratinocytes by upregulating BRD4. Int. Immunopharmacol. 119, 110095.
<https://doi.org/10.1016/j.intimp.2023.110095>
27. , X., Lai, Y. (2020) Keratinocyte: a trigger or an executor of psoriasis? J. Leukoc. Biol. 108, 485-491.
<https://doi.org/10.1002/JLB.5MR0120-439R>
28. , A., Bereza-Malcolm, L., Lynch, T. (2021) Skin barrier dysregulation in psoriasis. Int. J. Mol. Sci. 22, 10841.
<https://doi.org/10.3390/ijms221910841>
29. , M., Huang, Y., Zhu, X. et al. (2019) MiR‑125b‑mediated regulation of cell proliferation through the Jagged‑1/Notch signaling pathway by inhibiting BRD4 expression in psoriasis. Mol. Med. Rep. 19, 5227-5236.
30. , M. M., de Morais, H., Dos Santos Silva, E. et al. (2018) The antioxidant gallic acid induces anxiolytic-, but not antidepressant-like effect, in streptozotocin-induced diabetes. Metab. Brain Dis. 33, 1573-1584.
<https://doi.org/10.1007/s11011-018-0264-9>
31. , R. G., Cano, A., Ortiz, A. et al. (2021) Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics. Int. J. Mol. Sci. 22, 4983.
<https://doi.org/10.3390/ijms22094983>
32. , A., Schäkel, K. (2019) Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20, 1475.
<https://doi.org/10.3390/ijms20061475>
33. , G., Ridha, Z., Simard, M. et al. (2020) Transcriptome profiling analyses in psoriasis: a dynamic contribution of keratinocytes to the pathogenesis. Genes (Basel) 11, 1155.
<https://doi.org/10.3390/genes11101155>
34. , A., Hazari, S. A., Molugulu, N. et al. (2023) Hyaluronic acid engineered gallic acid embedded chitosan nanoparticle as an effective delivery system for treatment of psoriasis. Environ. Res. 238 (Pt 1), 117086.
<https://doi.org/10.1016/j.envres.2023.117086>
35. , S., Yang, L., Yang, Y. et al. (2021) Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 12, 1009.
<https://doi.org/10.1038/s41419-021-04284-5>
36. , F., Dianat, M., Badavi, M. et al. (2020) Does gallic acid improve cardiac function by attenuation of oxidative stress and inflammation in an elastase-induced lung injury? Iran J. Basic Med. Sci. 23, 1130-1138.
37. , X., Yang, P. (2021) Inhibition of BRD4 inhibits proliferation and promotes apoptosis of psoriatic keratinocytes. Biomed. Eng. Online 20, 107.
<https://doi.org/10.1186/s12938-021-00943-y>
38. , M., Mabuchi, T. (2020) New treatment addressing the pathogenesis of psoriasis. Int. J. Mol. Sci. 21, 7488.
<https://doi.org/10.3390/ijms21207488>
39. , S. G., Apostolopoulou, K., Mavropoulos, A. et al. (2023) Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-17-producing sub-populations in vitro in patients with psoriasis. Immunol. Res. 71, 475-487.
<https://doi.org/10.1007/s12026-023-09361-9>
40. , J., Yin, Z., Guo, J. et al. (2020) Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ. Int. Immunopharmacol. 79, 106045.
<https://doi.org/10.1016/j.intimp.2019.106045>
41. , M., Kaštelan, M., Brajac, I. et al. (2021) Current concepts of psoriasis immunopathogenesis. Int. J. Mol. Sci. 22, 11574.
<https://doi.org/10.3390/ijms222111574>
42. , J., Xu, Y., Rao, X. et al. (2022) BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin. Transl. Med. 12, e718.
<https://doi.org/10.1002/ctm2.718>
43. , W., Tang, Y. A., Xiao, Q. et al. (2021) Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal cancer. Nat. Commun. 12, 4441.
<https://doi.org/10.1038/s41467-021-24687-4>
44. , X., Zhao, H., Ma, C. et al. (2018) Gallic acid attenuates allergic airway inflammation via suppressed interleukin-33 and group 2 innate lymphoid cells in ovalbumin-induced asthma in mice. Int. Forum Allergy Rhinol. 8, 1284-1290.
<https://doi.org/10.1002/alr.22207>
45. , S. Y., Lee, C. F., Lai, H. T. et al. (2020) Opposing functions of BRD4 isoforms in breast cancer. Mol. Cell. 78, 1114-1132.
<https://doi.org/10.1016/j.molcel.2020.04.034>
46. , Y., Tang, G., Zhang, C. et al. (2021) Gallic acid and diabetes mellitus: its association with oxidative stress. Molecules 26, 7115.
<https://doi.org/10.3390/molecules26237115>
47. , X., Zhang, Y. L., Zhang, L. et al. (2019) Gallic acid suppresses cardiac hypertrophic remodeling and heart failure. Mol. Nutr. Food Res. 63, e1800807.
<https://doi.org/10.1002/mnfr.201800807>
48. , J., Li, X., Wei, J. et al. (2018) Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease. Int. Immunopharmacol. 65, 84-95.
<https://doi.org/10.1016/j.intimp.2018.09.048>
49. , X., Chen, Y., Cui, C. et al. (2022) Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 13, 81.
<https://doi.org/10.1038/s41419-022-04523-3>
